Beitz J - Search Results

1

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R. Bross PF, et al. Among authors: beitz j. Clin Cancer Res. 2001 Jun;7(6):1490-6. Clin Cancer Res. 2001. PMID: 11410481

2

Predictive value of preclinical toxicology studies for platinum anticancer drugs.

Clark DL, Andrews PA, Smith DD, DeGeorge JJ, Justice RL, Beitz JG. Clark DL, et al. Among authors: beitz jg. Clin Cancer Res. 1999 May;5(5):1161-7. Clin Cancer Res. 1999. PMID: 10353752

3

Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective.

Beitz J, Gnecco C, Justice R. Beitz J, et al. J Natl Cancer Inst Monogr. 1996;(20):7-9. J Natl Cancer Inst Monogr. 1996. PMID: 8750460

4

Trial endpoints for drug approval in oncology: Chemoprevention.

Beitz J. Beitz J. Urology. 2001 Apr;57(4 Suppl 1):213-5. doi: 10.1016/s0090-4295(00)00977-8. Urology. 2001. PMID: 11295630

5

Protocol design considerations that relate to demonstrating the safety and effectiveness of chemopreventive agents.

Johnson KA, Beitz J, Justice R, Schmidt W, Andrews P, DeLap R. Johnson KA, et al. Among authors: beitz j. J Cell Biochem Suppl. 1997;27:1-6. J Cell Biochem Suppl. 1997. PMID: 9591186

6

Reconsideration of 2008 decision: Food and Drug Administration approval of etanercept for systemic treatment of moderate to severe pediatric psoriasis.

Gatti J, Lindstrom JA, Beitz J. Gatti J, et al. Among authors: beitz j. Pediatr Dermatol. 2018 Sep;35(5):688-689. doi: 10.1111/pde.13557. Epub 2018 Jul 31. Pediatr Dermatol. 2018. PMID: 30066378

7

Deaths associated with inappropriate intravenous colchicine administration.

Bonnel RA, Villalba ML, Karwoski CB, Beitz J. Bonnel RA, et al. Among authors: beitz j. J Emerg Med. 2002 May;22(4):385-7. doi: 10.1016/s0736-4679(02)00430-4. J Emerg Med. 2002. PMID: 12113850

8

Renal failure associated with the use of celecoxib and rofecoxib.

Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J. Ahmad SR, et al. Among authors: beitz j. Drug Saf. 2002;25(7):537-44. doi: 10.2165/00002018-200225070-00007. Drug Saf. 2002. PMID: 12093311 Review.

9

Quality-of-life end points in oncology drug trials.

Beitz J. Beitz J. Oncology (Williston Park). 1999 Oct;13(10):1439-42; discussion 1442 passim. Oncology (Williston Park). 1999. PMID: 10549568 Free article. Review.

10

Changes in ciprofloxacin utilization as shown in a large pharmacy claims database: effects of proximity to criminal anthrax exposure in October 2001.

Brinker A, Pamer C, Beitz J. Brinker A, et al. Among authors: beitz j. J Am Pharm Assoc (2003). 2003 May-Jun;43(3):375-8. doi: 10.1331/154434503321831085. J Am Pharm Assoc (2003). 2003. PMID: 12836787

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

222 results

Search Page

Filters